Multi-step approach for automated scaling of photogrammetric micro-measurements

[EN] Photogrammetry can be used for the measurement of small objects with micro-features, with good results, low costs, and the possible addition of texture information to the 3D models. The performance of this technique is strongly affected by the scaling method, since it retrieves a model that must be scaled after its elaboration. In this paper, a fully automated multi-step scaling system is presented, which is based on machine vision algorithms for retrieving blurred areas. This method allows researchers to find the correct scale factor for a photogrammetric micro model and is experimentally compared to the existing manual method basing on the German guideline VDI/VDE 2634, Part 3. The experimental tests are performed on millimeter-sized certified workpieces, finding micrometric errors, when referred to reference measurements. As a consequence, the method is candidate to be used for measurements of micro-features. The proposed tool improves the performance of the manual method by eliminating operator-dependent procedures. The software tool is available online as supplementary material and represents a powerful tool to face scaling issues of micro-photogrammetric activities.Frangione, A.; Sánchez Salmerón, AJ.; Modica, F.; Percoco, G. (2019). Multi-step approach for automated scaling of photogrammetric micro-measurements. The International Journal of Advanced Manufacturing Technology. 102(1-4):747-757. https://doi.org/10.1007/s00170-018-03258-w7477571021-

Short-term efficacy and safety of betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis: Results of a randomised, double blind, placebo-controlled study

Background. This placebo-controlled, double-blind study evaluated the short-term effects of betamethasone valerate (BMV) 2.25mg medicated plaster in patients with chronic lateral elbow tendinopathy (LET). Methods. Adult outpatients with LET and on-movement pain intensity ≥50 mm at a 0-100mm visual analogue scale (VAS) were randomised to receive BMV (N=101) or placebo (N=98), 12 hours/day for 4 weeks. Pain decrease from baseline to Day 28 was the primary endpoint. Other endpoints were: patient-rated tennis elbow evaluation (PRTEE), use of rescue paracetamol, tolerability at the application site. Results. Decrease in mean pain VAS from baseline to Day 28 was significantly higher with BMV vs. placebo: the difference between groups (intent-to-treat) was-8.57 mm (95% CI:-16.19 to-0.95 mm; p=0.028). Higher pain decreases in the BMV group over placebo were reported weekly during each control visit and daily in patients’ measurements on diaries. Treatment with BMV also led to higher decreases vs. placebo in PRTEE total, pain and functional disability score. Use of paracetamol was minimal. BMV plaster was well tolerated for general and local adverse events. Conclusions. BMV 2.25mg plaster was superior to placebo and well tolerated in patients with painful chronic LET

Prevention of suicide behind bars: first Italian results

Background: The reduction of suicides in jails and prisons is an international priority and, after the publication of a report about the necessity to prevent the suicide risk, in Tuscany (Italy) was created a new biphasic protocol. The aim of our study was to show the preliminary results after the introduction of this protocol in the Penitentiary of Pistoia. Methods: We conducted an ecological pilot study from April to December 2016. In the Penitentiary of Pistoia, a multidisciplinary staff collected socio-demographic and clinical information of the new inmates, and estimated the suicide risk administering the Arboleda-Florez Checklist. Results: Ninety-three new prisoners (all males) were conducted in the Penitentiary of Pistoia: 12 (12.90%) came from another prison; 81 (87.09%) were free before the arrival. 16 (17.2%) were homeless, 52 (55.91%) were unemployed, 1 (1.07%) was retired. 32 declared to use drugs; 7 of them declared also the alcohol abuse. Three detainees claimed only the alcohol abuse. 9 prisoners were already assisted by the Service for Drug Addiction when they have been arrested. 77 (82.79%) were positive for at least 1 item of the Arboleda-Florez Checklist. The measures of great surveillance were disposed for 67 prisoners. Three were the measures of Greatest Surveillance for high suicide risk. 13 inmates needed a specific pharmacological treatment prescribed by a psychiatrist. A therapy for mild anxiety and insomnia was prescribed in 29 cases: 21 after the first visit; 8 later. A psychological support was furnished to 23 prisoners who didn’t need the prescription of psychotropic medication, but only an emotional support. Conclusions: Our pilot study showed that the biphasic protocol could be able to manage in a good way the suicide risk, in fact no suicide occurred in the examined period of time. However, studies covering longer periods of time and involving other realities are needed to give more reliable results about its real efficacy

Copper chelation delays the onset of prion disease.

The prion protein (PrP) binds copper and under some conditions copper can facilitate its folding into a more protease resistant form. Hence, copper levels may influence the infectivity of the scrapie form of prion protein (PrP Sc ). To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, D-(؊)-penicillamine (D-PEN), starting immediately following intraperitoneal scrapie inoculation. D-PEN delayed the onset of prion disease in the mice by about 11 days (p ‫؍‬ 0.002), and reduced copper levels in brain by 29% (p < 0.01) and in blood by 22% (p ‫؍‬ 0.03) compared with control animals. Levels of other metals were not significantly altered in the blood or brain. Modest correlation was observed between incubation period and levels of copper in brain (p ‫؍‬ 0.08) or blood (p ‫؍‬ 0.04), indicating that copper levels are only one of many factors that influence the rate of progression of prion disease. In vitro, copper dose-dependently enhanced the proteinase K resistance of the prion protein, and this effect was counteracted in a dose-dependent manner by co-incubation with D-PEN. Overall, these findings indicate that copper levels can influence the conformational state of PrP, thereby enhancing its infectivity, and this effect can be attenuated by chelatorbased therapy

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

Present immunoprevention and immunotherapeutic approaches against cancer suffer from the limitation of being not “sterilizing” procedures, as very poor protection against the tumor is obtained. Thus newly conceived anti-tumor vaccination strategies are urgently needed. In this review we will focus on ways to provide optimal MHC class II-restricted tumor antigen presentation to CD4+ T helper cells as a crucial parameter to get optimal and protective adaptive immune response against tumor. Through the description of successful preventive or therapeutic experimental approaches to vaccinate the host against the tumor we will show that optimal activation of MHC class II-restricted tumor specific CD4+ T helper cells can be achieved in various ways. Interestingly, the success in tumor eradication and/or growth arrest generated by classical therapies such as radiotherapy and chemotherapy in some instances can be re-interpreted on the basis of an adaptive immune response induced by providing suitable access of tumor-associated antigens to MHC class II molecules. Therefore, focussing on strategies to generate better and suitable MHC class II–restricted activation of tumor specific CD4+ T helper cells may have an important impact on fighting and defeating cancer